Quantum Leap
Canada
Funding for biopharmaceutical R&D
grant_single|update March 6, 2025
grant_single_labels|summary
grant_single|eligibleFinancing
- grant_single|fromMinToMax
- grant_single|projectCostPercent
grant_single|deadlines
- grant_single|timelineUnspecified
grant_single|financingType
Grant and Funding
grant_single|eligibleIndustries
- Health care and social assistance
grant_single|grantors
- Quebec Consortium for Drug Discovery (CQDM)
grant_single|status
grant_card_status|open
grant_single_labels|preview
Get a grant between $500,000 and $1.2 million for R&D related to innovative technologies, tools and platforms that facilitate the drug discovery/development process and new therapeutic approaches.
grant_single_labels|terms_and_conditions
- Funding from CQDM typically covers one-third (1/3) of the total project budget, although this percentage can vary depending on the project's nature.
- CQDM's pharmaceutical members are expected to provide financial support equivalent to approximately one-third (1/3) of the project’s value.
- Candidates are responsible for acquiring the remaining funds required for the project. CQDM offers assistance in securing funds from potential co-funding partners.
- Projects generally range from $500,000 to $1,500,000, though applications exceeding this range may be considered in exceptional cases if justified.
- Funding might be provided as a grant or investment.
- Detailed budget justifications are required and will be thoroughly reviewed by CQDM.
- CQDM has the ability to form partnerships with national and international organizations for co-funding possibilities.
- Guaranteed funding commitments from private, semi-private, or not-for-profit public organizations can offer an advantage in the selection process.
grant_single_labels|projects
- Innovative translational R&D projects in collaboration with large biopharmaceutical organizations.
- Development of cutting-edge technologies for enhancing R&D activities.
- Creation of enabling technologies, pioneering platforms, and innovative therapeutic methods targeting drug development stages.
- Projects aimed at considerably accelerating the discovery and development of safer, more effective drugs.
grant_single|admissibleProjectsExample
$ 900,000
Creation of a computational platform for drug-target interaction studies
$ 750,000
Development of AI-driven drug discovery platform
$ 1,000,000
Implementation of a high-throughput screening system for drug candidates
$ 900,000
Design of a nanotechnology-based drug delivery system
$ 1,100,000
Development of genomic analysis tools for personalized medicine
$ 850,000
Creation of a biotechnological tool for faster drug development
grant_single_labels|admissibility
- The applicant must be a Canadian SME or a public research institution.
- The project should involve innovative translational R&D in collaboration with large biopharmaceutical organizations.
- The project must aim to develop enabling technologies, pioneering platforms, or innovative therapeutic methods targeting all stages of drug development.
grant_eligibility_criteria|who_can_apply
- Canadian SMEs (Small and Medium-sized Enterprises)
- Public research institutions
grant_eligibility_criteria|who_cannot_apply
Some types of companies may not be eligible for this grant due to specific criteria. These companies may include:
- Companies operating outside of Canada
- Non-profit organizations
grant_eligibility_criteria|eligible_expenses
- Grants, salaries and social benefits for research staff working on the project, including technicians, assistants, and research associates, post-doctorates and students.
- Equipment, consumables, and laboratory supplies, including platform and animal fees.
- Travel fees for project-related travel, collaborations, and conferences, as well as fees associated with the dissemination of knowledge.
- Costs related to intellectual property, such as patent applications and maintenance fees for the duration of the project.
- Purchase or rental of small pieces of equipment with a maximum value of $25,000.
- Payments made to subcontracted businesses not project partners when the activity is essential and cannot be performed by the research institution or SME.
grant_eligibility_criteria|zone
- Canadian SMEs (Small and Medium-sized Enterprises).
- Public research institutions based in Canada.
grant_single_labels|criteria
- Impact on the potential development of new drugs and ability to address critical needs in the biopharmaceutical field.
- Scientific excellence, including the innovative aspect of the research and the quality of the experimental plan.
- Feasibility, assessed by the current development status of the technology, preliminary data, milestones, and planned deliverables.
- Positioning and competitive advantage, evaluating the innovation's uniqueness and its benefit over international competitors.
- Marketing potential, with a focus on developing a suitable maturation plan and fulfilling biopharmaceutical needs, including main milestones and required funds at each stage.
- Quality of the business plan, where applicable for SMEs.
- Economic benefits, such as potential gains for all partners and strategic alignment with SMEs' corporate objectives.
- Team quality, relevance, and synergy of the project partners.
grant_single_labels|register
- Step 1: Fill Non-Confidential FormDownload and complete the summarized non-confidential form.
- Ensure all required fields and information are provided accurately.
- Step 2: Submit Preliminary ApplicationEmail the completed form to [email protected].
- Submission can be done at any time.
- Contact Jesse Paterson for any queries about the application process.
- Step 3: Video PresentationIf pre-selected, prepare a video presentation of your project.
- The video will be shared with CQDM's pharmaceutical members.
- Step 4: Comprehensive ApplicationInvited candidates will prepare a full confidential application.
- Incorporate feedback, questions, and concerns from pharmaceutical members.
grant_single_labels|otherInfo
- Projects must generate tangible deliverables to benefit CQDM's pharmaceutical members.
- Engagement with CQDM's pharmaceutical members is crucial for developing the final project and experimental design.
- Grants may include funds from various national and international partnerships coordinated by CQDM.
- The opportunity is available for projects to secure future collaborations with the global industry.
- Final terms for intellectual property and licensing policies are negotiated prior to project start, based on existing property and party contributions.
- Submissions do not constitute licensing commitments at the initial application stage.
